Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12910368 | 0.90 | NPC1 (0.43) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL12910369 | 0.85 | HSD17B10 (0.48) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL12910360 | 0.84 | NPC1 (0.45) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL12910363 | 0.80 | NPC1 (0.64) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL220096 | 0.79 | NPC1 (0.63) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL9867389 | 0.78 | SMN1; SMN2 (0.54) | NPC1RAB9AKDM4EALDH1A1NFKB1 | |
| SCHEMBL12910349 | 0.77 | NPC1 (0.40) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL22824545 | 0.76 | BCHE (0.48) | NPC1RAB9AKDM4EADORA2AADORA1 | |
| SCHEMBL12910370 | 0.76 | NPC1 (0.47) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL10279237 | 0.76 | NPC1 (0.43) | NPC1RAB9AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875368-B2 | benzoxazole or imidazolopyridine compounds and charge transfer compounds, interposed between a pair of electrodes, to form organic electroluminescent devices, having high emission luminance and efficiency | CANON KABUSHIKI KAISHA (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7875368-B2 | benzoxazole or imidazolopyridine compounds and charge transfer compounds, interposed between a pair of electrodes, to form organic electroluminescent devices, having high emission luminance and efficiency | CANON KABUSHIKI KAISHA (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20080138656-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080138656-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138656-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | CRY1, ORC3, OXER1 | NPC1 3514/4885RAB9A 2099/4885KDM4E 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.